MARKET

RPRX

RPRX

Royalty Pharma Plc
NASDAQ
26.43
+0.03
+0.11%
After Hours: 26.42 -0.01 -0.04% 18:02 11/22 EST
OPEN
26.38
PREV CLOSE
26.40
HIGH
26.63
LOW
26.33
VOLUME
2.46M
TURNOVER
--
52 WEEK HIGH
30.92
52 WEEK LOW
24.80
MARKET CAP
15.57B
P/E (TTM)
10.33
1D
5D
1M
3M
1Y
5Y
1D
Royalty Pharma price target raised to $39 from $38 at BofA
TipRanks · 5d ago
Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
TipRanks · 5d ago
Weekly Report: what happened at RPRX last week (1111-1115)?
Weekly Report · 6d ago
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +
Seeking Alpha · 11/16 13:00
ROYALTY PHARMA ANNOUNCES INAUGURAL PRIZE FOR IMPACT IN HEALTHCARE
Reuters · 11/14 21:30
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Barchart · 11/14 15:30
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
The Motley Fool · 11/14 10:20
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Simply Wall St · 11/13 12:13
More
About RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Webull offers Royalty Pharma plc stock information, including NASDAQ: RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.